marked.bio

BCL-2/BCL-xL inhibitor · small molecule

navitoclax

3 active trials across 5 of our biomarkers, targeting BCL-2/BCL-xL. Not approved for any biomarker on marked.bio yet.

Also known as ABT-263.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
BRAF V600E 1 1 Phase 1/2
BRCA1/2 mutation 1 1 Phase 1
KRAS G12C 1 1 Phase 1/2
KRAS G12D 1 1 Phase 1/2
EGFR exon 19 deletion / L858R 0 1 –

Trials

3 of 4 trials shown

  1. Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

    Active, not recruiting Phase 1/2 National Cancer Institute (NCI) Started 2014Primary completion 2022-12 NCT02079740

    navitoclaxtrametinib

    Patients must have histologically- or cytologically-confirmed diagnosis of KRAS or NRAS mutation-positive malignancy that is metastatic or unresectable and for which standard curative me…

    KRAS G12CKRAS G12DMetastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm

  2. Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma

    Active, not recruiting Phase 1/2 National Cancer Institute (NCI) Started 2014Primary completion 2027-12 NCT01989585

    dabrafenib FDA EUnavitoclaxtrametinib FDA EU

    Patients must have histologically confirmed, BRAF-mutant (V600E/K) melanoma (molecularly confirmed using validated, commercially available assay performed …

    BRAF V600EClinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Malignant Solid Neoplasm, Metastatic Melanoma

  3. Combination of Olaparib and Navitoclax in Women with HGSC and TNBC

    Active, not recruiting Phase 1 Sunnybrook Health Sciences Centre Started 2022Primary completion 2025-03 NCT05358639

    olaparib FDA EUnavitoclax

    Metastatic TNBC: tumors that are known to have deleterious somatic or germline mutations in BRCA1, BRCA2, or PALB2.

    BRCA1/2 mutationHigh Grade Serous Carcinoma, Triple Negative Breast Cancer, Ovarian Cancer